Our observation that phosphorylated CDK4 is the major modified form of CDK4 in a subgroup of basal‐like tumors and most HER2‐positive breast tumors provides objective arguments for extending the use of CDK4 inhibitors to these ER‐negative tumors. The gene discussed is ERBB2; the disease is breast neoplasm.